In final draft guidance the National Institute for Health and Clinical Excellence (NICE) recommends the use of mifamurtide in combination with postoperative multi-agent chemotherapy as an option for treating high-grade resectable non-metastatic osteosarcoma, when it is made available at a reduced cost to the NHS under a patient access scheme.
MTX Healthcare is a division of MTX Contracts Limited, specialising in the design, installation and engineering of operating theatre suites and other high care healthcare facilities. With a strong commitment to quality and service, we aim at all times to provide a long lasting efficient and cost effective solution to our customers requirements to...
University of Warwick
8th - 9th August 2025
Stansted Radisson Blu
23rd September 2025
Brighton Centre, UK
29th - 30th September 2025
EICC, Edinburgh
16th - 18th November 2025
